Nadler Financial Group adds Eli Lilly and Co (LLY) to its portfolio

Eli Lilly and Co (LLY) : Nadler Financial Group added new position in Eli Lilly and Co during the most recent quarter end. The investment management firm now holds 2,650 shares of Eli Lilly and Co which is valued at $217,539 , the company said in a statement filed on Oct 7, 2016 with the SEC.Eli Lilly and Co makes up approximately 0.09% of Nadler Financial Group’s portfolio.

Other Hedge Funds, Including , Advisory Services Network reduced its stake in LLY by selling 172 shares or 2.17% in the most recent quarter. The Hedge Fund company now holds 7,740 shares of LLY which is valued at $635,377. Eli Lilly and Co makes up approx 0.12% of Advisory Services Network’s portfolio.Acropolis Investment Management reduced its stake in LLY by selling 295 shares or 11.65% in the most recent quarter. The Hedge Fund company now holds 2,237 shares of LLY which is valued at $182,875. Eli Lilly and Co makes up approx 0.03% of Acropolis Investment Management’s portfolio. New England Research Management sold out all of its stake in LLY during the most recent quarter. The investment firm sold 7,400 shares of LLY which is valued $604,950.Lynch Associatesin reduced its stake in LLY by selling 12 shares or 0.17% in the most recent quarter. The Hedge Fund company now holds 6,999 shares of LLY which is valued at $572,168. Eli Lilly and Co makes up approx 0.25% of Lynch Associatesin’s portfolio.

Eli Lilly and Co opened for trading at $81.57 and hit $82.31 on the upside on Friday, eventually ending the session at $82.09, with a gain of 0.76% or 0.62 points. The heightened volatility saw the trading volume jump to 42,41,408 shares. Company has a market cap of $90,615 M.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Many Wall Street Analysts have commented on Eli Lilly and Co. Eli Lilly and Co was Upgraded by Goldman to ” Buy” on Sep 27, 2016. Eli Lilly and Co was Upgraded by JP Morgan to ” Overweight” on Sep 8, 2016.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.